PMS2 and breast cancer: Considering a distinction for pathology, among the sixteen BC patients with no other LP/P variants, three harboured VUS in the BRCA1 gene (18.7%), four patients harboured VUS in the ATM (25%), five VUS in CHEK2 (31.2%), one in MSH6 gene (6.2%), one in MLH1 (6.2%) and two in PMS2 (12.5%) (Table 2).